Verified July 2026 · Cited to primary sources
Peptides marketed for hair growth, graded by human evidence and legal status. The short answer: peptide hair evidence is early and thin, and the strongest proven hair treatments (finasteride and minoxidil) are not peptides at all.
Evidence for this goal
The only peptide here with genuine human evidence is topical GHK-Cu (copper peptides), and even that is Grade B for skin with only early, thin hair data, nowhere near the proof behind finasteride and minoxidil, which are not peptides. If regrowing hair is the goal, the evidence points to those proven drugs first. A copper-peptide serum is at best a legal, low-risk supporting cosmetic.
How to read this comparison
Compounds are listed alphabetically, not ranked for this goal. The overall grade reflects the evidence described in each record. Evidence for one condition, population or product form does not establish benefit for every use. Affiliate availability never changes a grade.
A historical FDA survey of compounded drugs found 31% failed standard potency testing. What is actually in the vial is a separate question from whether the compound works, and a rubric like this exists to keep the two apart. See the full A to F methodology →
Evidence scope: Grade B for TOPICAL/cosmetic use. GHK-Cu has real, decades-long human topical evidence (Pickart's tissue-remodeling work plus controlled cosmetic studies on aging skin) but is not an FDA-approved drug (rule 3 boundary: real but limited human data, no drug approval). Important split: INJECTED/systemic GHK-Cu has only preclinical data and no legal supervised route, so that form is Grade D and unapproved. This record grades the topical cosmetic lane, which is the legal, evidenced one.
Sources: Pickart, J Biomater Sci Polym Ed 2008: the human tripeptide GHK and tissue remodeling (review) · FDA 503A bulks list (injectable GHK-Cu removed from Category 2; topical cosmetic use is a separate legal channel)
A copper-binding tripeptide that stimulates collagen and elastin synthesis, activates fibroblasts, and supports wound repair. Its strongest evidence is topical, on skin.
GHK-Cu (copper peptides) is legal as a topical cosmetic, and for skin its human evidence is Grade B: real topical/cosmetic data, no drug approval. Injected GHK-Cu is a different, unapproved story (Grade D, no legal route). For skin or hair, the topical serum is the evidenced, legal choice. You don't need to inject anything.
See the evidence →| Peptide | Overall grade | Legal & safety | Typical cost | Verdict | |
|---|---|---|---|---|---|
| GHK-Cu The copper peptide behind decades of skincare. Real human topical/cosmetic evidence for skin, but injected versions are a different, unproven story. | Grade B | See evidenceSee the evidence for GHK-Cu |
Reading this table: Grades refer to each compound's stated evidence scope, not every use in this category. Legal status and Safety are separate badges; Verdict is the compound summary. Affiliate availability never changes a grade. Full methodology.
FAQ
No peptide has strong hair-growth proof. Topical GHK-Cu (copper peptides) is the only one with genuine human evidence, and even that is early and thin for hair specifically. The strongest proven hair treatments, finasteride and minoxidil, are not peptides, so for actual regrowth the evidence points to those first.
The hair evidence for GHK-Cu is early and small, nothing approaching the proof behind finasteride or minoxidil. Copper peptides may play a supporting cosmetic role and are legal and low-risk as a topical, but they are not a proven hair-loss treatment on their own.
Topical copper-peptide serums are legal cosmetics and generally very well tolerated. Injectable peptides marketed for hair have no human efficacy trials and no legal supervised US route. The proven, well-characterized hair treatments (finasteride, minoxidil) are regulated drugs, and they aren't peptides.
Read the evidence
Before you buy anything
Other goals
The monthly peptide evidence brief.
What the research and the FDA actually say, in one short email a month. Unsubscribe anytime.
No spam. We never sell your email. Editorial policy.